1. Home
  2. |Insights
  3. |The False Claims Act: Qui Tam Whistleblower Litigation and Investigations

The False Claims Act: Qui Tam Whistleblower Litigation and Investigations

Webinar | 10.17.18, 8:00 AM EDT - 9:00 AM EDT

With treble damages against defendants and qui tam relator shares of up to 30% of those damages, plus reasonable attorney fees in successful suits, the FCA provides strong incentives for whistleblowers to bring qui tam actions, making it no surprise that most FCA actions are initiated by relators. Whether DOJ intervenes or not, FCA qui tam actions pose a variety of unique issues and challenges. In this webinar, we’ll discuss the peculiarities of qui tam actions and offer practical insights and strategies for the investigation and litigation of these cases.


Contact

Insights

Webinar | 12.10.26

The Third-Party Perspective: Protecting Payors’ Interests in Antitrust Investigations

The Trump administration has sharpened its focus on hospital systems as a key driver of rising health care costs, and the DOJ and FTC are actively patrolling for anticompetitive conduct and mergers that contribute to these rising costs. Managed care organizations are a critical source of evidence in these investigations and are likely to receive Civil Investigative Demands (CIDs), be contacted by agency staff, or may consider proactively engaging with antitrust authorities to address competitive concerns in their markets.